Company news

Enveric Biosciences, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Enveric Biosciences Receives Notice of Allowance for New Class of Low-Hallucinogenic Neuroplastogens Targeting Psychiatric Disorders

June 10, 2025

Enveric Biosciences Announces Issuance of U.S. Patent Covering a Novel Family of Molecules Including Melatonin Receptor-Targeting Compounds

June 3, 2025

Enveric Biosciences Reports Positive Preclinical Results for Lead Drug Candidate EB-003

May 28, 2025

Enveric Biosciences Identifies Neuroplastogen Candidates with Potential to Address Neurodegenerative Disease

May 20, 2025

Enveric Biosciences Reports First Quarter 2025 Financial and Corporate Results

May 14, 2025

Enveric Biosciences Reports Financial Results and Provides Corporate Update for Fourth Quarter and Fiscal Year Ended 2024

March 31, 2025

Enveric Biosciences Participating in BIO-Europe Spring®

March 17, 2025

Enveric Biosciences Launches Request-For-Proposals Solicitation Process for PsyAI Trademark

March 6, 2025

Enveric Biosciences CEO Issues Letter to Shareholders

February 27, 2025

Enveric Biosciences Unveils EVM401 Series of Compounds with New U.S. Patent

February 25, 2025

Enveric Biosciences and Restoration Biologics Announce Licensing Agreements to Treat Joint Disease

February 3, 2025

Enveric Biosciences Announces Closing of $5 Million Public Offering

February 2, 2025

Enveric Biosciences Announces Pricing of $5 Million Public Offering

January 29, 2025

Enveric Biosciences Announces New U.S. Patents Supporting EVM301 Series and EVM201 Series Compounds

December 1, 2024

Enveric Biosciences Preclinical Pharmacokinetic Studies of EB-003 Support Oral Bioavailability, Demonstrate Brain Penetration, and Show No Evidence of Hallucination-like Behavior

November 24, 2024

Enveric Biosciences Reports Third Quarter 2024 Financial and Corporate Results

November 13, 2024

Enveric Biosciences Signs Out-Licensing Agreement with MycoMedica Life Sciences for EB-002

November 11, 2024

Enveric Biosciences Announces Broad Range of Patent Issuances

November 3, 2024

Enveric Biosciences Announces Positive Pharmacology and Safety Data for Lead Product, EB-003

October 14, 2024

Enveric Biosciences Presents Data on Lead Product Candidate, EB-003, at 7th Neuropsychiatric Drug Summit

September 24, 2024

Enveric Biosciences Reports Second Quarter 2024 Financial and Corporate Results

August 11, 2024

Enveric Biosciences Announces Preclinical Results Confirming Potential of EB-003 to be Dosed Orally

July 24, 2024

Enveric Biosciences Announces Patent Granted for Drug Candidate

July 9, 2024

Enveric Biosciences Provides Strategic Outlook and Pipeline Update, Elevating EB-003 to Lead Development Candidate

June 24, 2024

Enveric Biosciences Reports First Quarter 2024 Financial and Corporate Results

May 14, 2024

Enveric Biosciences Announces Signing of Non-Binding Term Sheet with Undisclosed Licensee for Exclusive License to Patented Methods of Treating Breast and Other Cancers Using Cannabinoids

May 7, 2024

Enveric Biosciences Reports Financial Results and Provides Corporate Update for Fourth Quarter and Fiscal Year Ended 2023

March 25, 2024

Enveric Biosciences Signs Non-Binding Term Sheets to Pursue the Exclusive Out-Licensing of New Chemical Entities for Pharmaceutical and Non-Pharmaceutical Applications in Joint Disease

March 18, 2024

Enveric Biosciences Announces New Patent Issuances Protecting Multiple Assets Covered by Non-Binding Term Sheets

March 11, 2024

Enveric Biosciences Agrees to Sell Cancer-Targeting Cannabinoid-Related Intellectual Property

February 22, 2024

Enveric Biosciences Unveils Library of Preclinical Compounds Across Multiple Distinct Molecule Classes Targeting Mental Health Disorders

February 20, 2024

Enveric Biosciences Updates Key Data Underpinning Selection of EB-003 as Lead Drug Candidate from EVM301 Series

January 2, 2024

Enveric Biosciences Announces Exercise of Warrants and Issuance of New Warrants in a Private Placement for $1.8 Million Gross Proceeds Priced At-the-Market

December 28, 2023

Enveric Biosciences Selects EB-003 as Lead Drug Candidate from EVM301 Series

December 27, 2023

Enveric Biosciences Reports Year End Progress for Preclinical Development of Lead Prodrug Candidate EB-373

December 26, 2023

Enveric Biosciences Receives Notice of Allowance from USPTO for Development of Glycosylated Psilocybin Derivatives

November 28, 2023

Enveric Biosciences Announces Presentation of Two Posters at Canadian Chemical Engineering Conference (CSChE 2023)

November 23, 2023

Enveric Biosciences Reports Third Quarter 2023 Corporate and Financial Results

November 12, 2023

Enveric Biosciences Receives Notice of Allowance from USPTO for Development of C4-Carbonothioate-substituted Tryptamine Derivatives for Novel Prodrug of Psilocin

October 30, 2023

Enveric Biosciences Initiates GLP Toxicology & Safety Pharmacology Studies for Lead Candidate EB-373, a Next Generation Psilocin Prodrug Targeting Psychiatric Disorders

October 17, 2023

Enveric Biosciences Announces Two Poster Presentations at the 6th Neuropsychiatric Drug Development Summit

October 10, 2023

Enveric Biosciences Announces its Psybrary™ Portfolio Now Totals Over 1000 Psychedelic-Inspired Therapeutic Candidates

October 2, 2023

Enveric Biosciences Announces Publication of a Paper Describing a Novel Bioproduction Platform for Psychedelic-Inspired Drug Discovery in the Journal of Biological Chemistry

September 26, 2023

Enveric Biosciences Expands IP Portfolio with New U.S. Patent for Novel Carboxylated Psilocybin Derivatives Supporting its EVM301 Series of Drug Candidates

September 19, 2023

Enveric Biosciences Files Provisional Patent Application for AI-based Computational Methods for Identifying and Optimizing Novel Tryptamine Derivatives

September 10, 2023

Enveric Biosciences Announces New U.S. Patent for C4-Carboxylic Acid-Substituted Tryptamine Derivatives

September 4, 2023

Enveric Biosciences Strengthens Intellectual Property Portfolio with New U.S. Patent for Tryptamine-derived Prodrugs

August 27, 2023

Enveric Biosciences Completes Manufacturing of EB-373 to Supply Drug Material for Completion of Preclinical Program

August 20, 2023

Enveric Biosciences Reports Second Quarter 2023 Corporate and Financial Results

August 13, 2023

Enveric Biosciences Reports Positive Results from Preclinical Studies Supporting Metabolic Profile of Lead Candidate EB-373

July 23, 2023

← Newer news releases · Older news releases →

Decks

The 5 newest of 15 decks. Every deck is listed under its year.